Impact of 1p/19q codeletion and histology on outcomes of XXXX treated with @entity1161 and temozolomide.

@entity1 @entity1313 @entity1161 @entity11 @entity816 @entity1485 @entity1349 @entity3271
PURPOSE: @entity11 represent a heterogeneous group of primary high-grade @entity1313 , and the optimal postoperative treatment remains controversial. In this report, we present our institutional data on the clinical outcomes of @entity1161 ( @entity1161 ) plus temozolomide ( @entity1161  +  TMZ) for @entity11 , stratified by histology and 1p/19q codeletion. METHODS AND MATERIALS: A single-institution retrospective review was conducted of @entity1 with supratentorial @entity3271 ( @entity3271 ), mixed @entity816 ( @entity816 ), and @entity816 ( @entity816 ). After surgery, @entity1161 was delivered at a median total dose of 60  Gy (range, 31.6-63  Gy) in daily fractions. All @entity1 received standard concurrent TMZ, with or without adjuvant TMZ. Histological/molecular subtypes were defined as codeleted @entity3271 / @entity816 , non-codeleted @entity3271 / @entity816 , and @entity816 . RESULTS: From 2000 to 2012, 111 cases met study criteria and were evaluable. Codeleted @entity3271 / @entity816 had superior @entity1349 ( @entity1349 ) to non-codeleted @entity3271 / @entity816 (91% vs 68% at 5  years, respectively, P=.02), whereas progression-free survival (PFS) was not significantly different (70% vs 46% at 5  years, respectively, P=.10). @entity816 had inferior @entity1349 to non-codeleted @entity3271 / @entity816 (37% vs 68% at 5  years, respectively, P=.007) and inferior PFS (27% vs 46%, respectively, P=.03). On multivariate analysis, age, performance status, and histological or molecular subtype were independent predictors for both PFS and @entity1349 . Compared to historical controls, @entity1161  +  TMZ provided comparable @entity1349 to @entity1161 with procarbazine, lomustine, and vincristine ( @entity1161  +  @entity1485 ) for codeleted @entity3271 / @entity816 , superior @entity1349 to @entity1161 alone for non-codeleted @entity3271 / @entity816 , and similar @entity1349 to @entity1161 alone for @entity816 . CONCLUSIONS: @entity1161  +  TMZ may be a promising treatment for both codeleted and non-codeleted @entity3271 / @entity816 , but its role for @entity816 remains unclear.
